- ASN002, an investigational dual inhibitor of Janus kinase (JAK) and spleen tyrosine kinase (SYK), showed good efficacy for moderate to severe atopic dermatitis in a phase 1b randomized controlled trial.
Why this matters
- Few oral treatments are available for treatment of AD.
- ASN002 was associated with superior efficacy compared with placebo:
- EASI-50 at day 29: 22.2% for placebo, 100.0% for 40 mg (P=.003 vs placebo), 83.3% for 80 mg (P=.03 vs placebo).
- EASI-75 at day 15: 42.9% for 40 mg (P=.04 vs placebo).
- Change from baseline in body surface affected at day 29: −3.2 for placebo, −21.6 for 40 mg (P=.03)
- Change from baseline in pruritus at day 29: −1.6 for placebo, −4.7 for 80 mg (P=.01).
- ASN002 induced significant and progressive reductions in the AD inflammatory serum signature.
- 2 adverse events that met the stopping rules occurred: 1 case of mild hypertension in a patient receiving ASN002 80 mg and 1 case of low lymphocyte levels in a patient receiving ASN002 40 mg.
- 36 patients with moderate to severe atopic dermatitis were randomly assigned 1:1:1:1 to ASN002 20 mg, ASN002 40 mg, ASN002 80 mg, or placebo over a 28-day period.
- Funding: Asana BioSciences.
- Small patient sample size.
- Short treatment duration.